NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer. The filing lists direct holdings of ordinary shares and stock options, including options over 6,500, 12,500 and 40,000 ordinary shares with exercise prices between $11.52 and $23.86 and expirations from 2031 to 2033. A footnote explains that certain ordinary shares represent restricted share units granted on February 5, 2026, vesting in two equal installments over 12 and 24 months.
Nano-X Imaging Ltd. executive Saban Sharon, General Manager of the AI Division, reported his initial beneficial ownership in the company. He holds 26,316 ordinary shares directly, including shares underlying restricted share units granted on February 5, 2026 that vest 50% after 12 months and 50% after 24 months from the grant date. He also holds a stock option covering 15,000 ordinary shares at an exercise price of $17.63 per share, granted on September 15, 2022. These options vest in 16 equal quarterly installments of 6.25% each and are scheduled to be fully exercisable by September 15, 2026, with an expiration date of September 15, 2032.
Nano-X Imaging Ltd. director Erez Alroy filed an initial ownership report showing direct holdings of the company’s ordinary shares and stock options. He reports 6,962 ordinary shares in one line and 17,544 ordinary shares in another, reflecting different grant types.
Alroy also holds stock options covering 50,000 ordinary shares with a fixed exercise price of $17.63 per share that expire on December 28, 2032, and options over 10,000 ordinary shares at $11.52 per share expiring on December 31, 2033. Footnotes explain that one ordinary-share position consists of restricted share units granted on December 10, 2025, vesting in twelve equal monthly installments over one year, and that the option grants vest in 16 equal quarterly installments over four years from their respective reference dates.
Nano-X Imaging Ltd files Amendment No. 1 to its Form F-3 registration statement to furnish the form of indenture as Exhibit 4.7 and an updated consent of its independent auditors. The prospectus in Part I is unchanged. The registration contemplates sales "from time to time after the effective date".
The filing also restates corporate governance provisions under Israeli law: the company’s articles permit exculpation, indemnification and officers’ insurance to the fullest extent allowed, and indemnification caps include $50 million, 25% of shareholders’ equity, or aggregate offering proceeds, as described. The amendment is signed by the CEO and authorized U.S. agent on March 26, 2026.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of ordinary shares back to the company. On March 18, 2026, he transferred 39,474 ordinary shares to the issuer at a stated price of $0.00 per share. After this issuer-related disposition, he directly holds 46,424 ordinary shares, according to the filing.
Nano-X Imaging Ltd. director Ronen Nehama filed an initial ownership report showing his equity position in the company. The filing lists a stock option to buy 50,000 ordinary shares at an exercise price of $17.63 per share, expiring on December 31, 2033, alongside direct holdings of ordinary shares, including shares underlying restricted share units that vest in twelve equal monthly installments from a December 10, 2025 grant.
Nano-X Imaging Ltd. director Kainan Noga filed an initial ownership report showing a mix of ordinary shares, restricted share units and stock options in the company. One block of ordinary shares consists of restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Noga also holds stock options over 12,505, 50,000 and 10,000 ordinary shares with exercise prices of $64.6100, $17.6300 and $11.5200, expiring in 2031, 2032 and 2033, respectively. Some ordinary shares are held indirectly through I.B.L. Business Consulting Ltd., which is wholly owned by Noga.
Nano-X Imaging Ltd. disclosed the initial holdings of Chief Executive Officer Erez Meltzer. He directly holds 60,584 ordinary shares. He also holds stock options over 40,234 ordinary shares at an exercise price of $2.2100 per share expiring on February 11, 2030, and options over 300,000 ordinary shares at $23.8400 per share expiring on January 2, 2032, both fully vested and exercisable. Additional options over 150,000 ordinary shares at $11.5200 per share expire on April 16, 2034 and vest over four years, with 25% vested after one year and 6.25% vesting quarterly until April 16, 2028.
Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.
Nano-X Imaging Ltd. Chief Legal Officer Marina Gofman Feler filed an initial ownership report on 2026-03-18. She holds stock options over 15,000 ordinary shares at an exercise price of 17.6300 expiring on 2032-11-07, options over 10,000 shares at 17.6300 expiring on 2033-04-28, and options over 30,000 shares at 11.5200 expiring on 2033-05-23.
She also holds 20,000 ordinary shares underlying restricted share units granted on 2026-02-05, which vest 50% on the 12-month anniversary of the grant date and 50% on the 24-month anniversary. A separate line shows 26,316 additional ordinary shares held directly.